Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 1,768
- 试验地点
- 23
- 主要终点
- Number of Participants Experiencing Treatment-emergent Adverse Events Considered Related to Florbetapir Administration
研究概览
简要总结
This protocol is designed to standardize imaging studies using florbetapir F 18 PET to provide information on amyloid burden in subjects participating in other studies (companion protocol) such as longitudinal studies of aging and studies of biomarkers for neurodegenerative diseases.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
Florbetapir-PET Scans
干预措施: Florbetapir F 18 (Drug)
结局指标
主要结局
Number of Participants Experiencing Treatment-emergent Adverse Events Considered Related to Florbetapir Administration
时间窗: 48 hours
Frequency of treatment-emergent adverse events considered related to florbetapir administration by the study investigator. Related events with a frequency \> 0.2% are reported. (note: all treatment-emergent adverse events, regardless of relatedness designation, are reported in "Adverse Events" section below)
次要结局
未报告次要终点